medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2005, Número 5

<< Anterior Siguiente >>

Rev Mex Urol 2005; 65 (5)


Prevalencia de cáncer prostático por toma de biopsia en pacientes con sospecha clínica

Cruz-Nuricumbo E, Gutiérrez-Ochoa A, Romero-Arriola H, Gaytán-Paz G, Nerubay-Toiber R, Gutiérrez-Godínez A

Idioma: Español
Referencias bibliográficas: 40
Paginas: 295-302
Archivo PDF: 87.53 Kb.


RESUMEN

Antecedentes. El cáncer de próstata ocupa a nivel mundial el segundo cáncer más frecuente de la población masculina. El ultrasonido transrectal con toma de biopsia prostática es un método común de evaluación y diagnóstico de cáncer de próstata. Objetivo. Identificar la prevalencia de cáncer de próstata, así como los diferentes diagnósticos histopatológicos de nuestra población de pacientes y correlacionar con los niveles de APE y el estado del tacto rectal. Metodología. Toma de biopsia transrectal guiada por USG a 266 pacientes y toma de APE. Resultados. El porcentaje de padecimientos benignos reportados fue de 78%, mientras que para procesos malignos y premalignos de 16 y 6%, respectivamente. Conclusiones. Consideramos que estamos subdiagnosticando a los pacientes con cáncer de próstata, debido a la relativa baja incidencia de nuestros resultados, en comparación con lo reportado internacionalmente. De tal forma, que necesitamos reducir el corte de APE por arriba de 2.5 ng/mL, para así aumentar el diagnóstico de cáncer prostático. El tacto rectal continúa siendo la piedra angular en el diagnóstico clínico de cáncer prostático.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Programa de acción contra el cáncer de próstata, SSA. 1ª edición, 2001.

  2. Martha KT. Ultrasonography and biopsy of prostate. In: Campbell’s Urology, 8th ed. Edited: Walsh PC, Retik AB, Vaughan ED, Wein AJ. 2002.

  3. Torres S. Estudio comparativo de la eficacia en la analgesia durante la toma de biopsia transrectal de próstata guiadas por ultrasonido: bloqueo de tronco nervioso vs. bloqueo de pedículo neurovascular. Rev Mex Urol 2003; 63(5): 191; 1-237.

  4. Cooner WH, Mosley BR, Rutherford CL Jr., Beard JH, Pond HS, Terry WJ, et al. Prostate cancer detection in a clinical urological practice by ultrasonography. Digital rectal examination and prostate specific antigen. J Urol 1990; 143: 1146.

  5. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specifi antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156.

  6. Stamey TA, McNeal JE. Adenocarcinoma of the prostate. In: Campbell’s Urology 6th ed. Edited: Walsh PC, Retik AB, Stamey TA, Vaughan ED Jr. Philadelphia: WB Saunders Co., 1992.

  7. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993: 270: 860.

  8. Richie JP, Catalona WJ, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology 1993; 42: 365.

  9. Carvalhal GF, Smith DS, Mager DE, Ramos C, Catalona WJ. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/mL or less. J Urol 1999; 161: 835.

  10. 10.Aboseif S, Shinohara K, Weider N, Narayan P, Carroll PR. The significance of prostatic intra-epithelial neoplasia. Br J Urol 1995; 76: 355.

  11. 11.Raviv G, Janseen T, Zlotta AR, Descamps F, Verhest A, Schulman CC. Prostatic intraepithelial neoplasia: influence of clinical and pathological data on the detection of prostate cancer. J Urol 1996; 156: 1050.

  12. 12.Langer JE, Rovner ES, Coleman BG, Yin D, Arger PH, Malkowicz SB, et al. Strategy for repeat biopsy of patients with prostatic intraepithelial neoplasia detected by prostate needle biopsy. J Urol 1996; 155: 228.

  13. 13.Wills ML, Hamper UM, Partin AW, Epstein JI. Incidence of high-grade prostatic intraepithelial neoplasia in sextant needle biopsy specimens. Urology; 49: 367.

  14. 14.O’dowd GJ, Miller MC, Orozco R, Veltri R W. Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. Urology 2000; 55: 553.

  15. 15.Davidson D, Bostwick DG, Qian J, Wollan PC, Oesterling JE, Rudders RA, et al. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. J Urol 1995; 154: 1295.

  16. 16.Berner A, Danielsen HE, Pettersen EO, Fossa SD, Reith A, Nesland JM. DNA distribution in the prostate. Normal gland, benign and premalignant lesions, and subsequent adenocarcinomas. Anal Quant Cytol Histol 1993; 15: 247.

  17. 17.Iczkowski KA, Bostwick DG. Prostate biopsy interpretation. Current concepts, 1999. Urol Clin North Am 1999; 26: 435.

  18. 18.Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994; 152: 1821.

  19. 19.Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991; 37: 1618.

  20. 20.Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliffe TL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214.

  21. 21.Catalona WJ, Partin AW, Slawin, KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542.

  22. 22.Chen YT, Luderer AA, Thiel RP, Carlson G, Cuny CL, Soriano TF. Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology 1996; 47: 518.

  23. 23.Carter HB, Pearson JD, Metter EJ, Brant L J, Chan DW, Andres R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215.

  24. 24.Smith DS, Catalona WJ. Rate of change of serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 1994: 152: 1163.

  25. 25.Matlaga BR, Eskew LA, McCullough DL. Prostate biopsy: indication and technique. J Urol 2003; 169: 12.

  26. 26.Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995; 154: 407.

  27. 27.Seaman E, Whang M, Olsson CA, Katz A, Cooner WH, Benson MC. PSA density (PSAD). Role in patient evaluation and management. Urol Clin North Am 1993; 20: 653.

  28. 28.Carey JM, Korman HJ. Transrectal ultrasound guided biopsy of the prostate. Do enemas decrease clinically significant complications? J Urol 2001; 166: 82.

  29. 29.Rodríguez LV, Terris MK. Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature. J Urol 1998; 160: 2115.

  30. 30.Kapoor DA, Klimberg IW, Malek GH, Wegenke JD, Cox CE, Patterson AL, et al. Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology 1998; 52: 552.

  31. 31.Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142: 71.

  32. 32.Levine MA, Ittman M, Melamed J, Lepor H. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol 1998; 159: 471.

  33. 33.Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157: 199,

  34. 34.Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001; 166: 86.

  35. 35.Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, Evans R, et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000; 163: 152.

  36. 36.Presti JC Jr., Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 2000; 163: 163.

  37. 37.Prostate Cancer Early Detection; Nacional Comprenhensive Cancer Network; 2004.

  38. 38.Catalona WJ, Ramos CG, Carvalhal GF, Yan Y. Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology 2000; 55: 791.

  39. 39.Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277: 1452.

  40. 40.Smith DS, Carvalhal GF, Mager DE, Bullock AD, Catalona WJ. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol 1998; 160: 134.




2020     |     www.medigraphic.com